PT-141 (Bremelanotide) research guide for 13. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
PT-141 (Bremelanotide) sourcing for researchers across 13 follows the universal online supply model — local retail for research peptides is essentially absent, making the ability to assess vendor documentation the foundation of reliable sourcing. For researchers in 13 beginning to work with PT-141 (Bremelanotide) the most efficient route is: find online research communities with active 13 participation and search for current vendor recommendations specific to your location. 13's position in the research peptide supply chain is primarily as a destination market served by international vendors — the analytical standards and handling protocols are no different from anywhere else in the world. What follows addresses the core quality standards for PT-141 (Bremelanotide) with 13-specific sourcing and shipping context added for 13-based researchers.
PT-141 (Bremelanotide): Research & Evidence
Aesthetic peptide research in 13 using compounds like PT-141 (Bremelanotide) requires experimental models appropriate to the specific research question. For skin-focused research: primary human fibroblast cultures for collagen synthesis studies; reconstructed human skin models (3D epidermis) for more complex endpoint measurement; and for in-vivo work, established rodent wound healing models. For pigmentation research: primary melanocyte cultures from human or mouse sources, with quantitative melanin content assay and MC1R expression measurement. The model selection should match the claimed mechanism of PT-141 (Bremelanotide) being investigated.
13 researchers sourcing PT-141 (Bremelanotide) should plan around typical shipping timelines: international peptide shipments to 13 typically take 5-15 business days depending on supplier geography and chosen delivery option. Quality markers remain the same regardless of destination: batch-matched COA with HPLC purity ≥98%, mass spec identity confirmation, and endotoxin data — all available prior to ordering. Storage infrastructure is a practical consideration 13 researchers should sort out ahead of placing any order — lyophilised peptides require −20°C storage, and ordering large quantities without proper storage in place is counterproductive to research quality. Avoid initiating time-dependent research without sufficient product already in storage given natural variation in international shipping timelines.
Research compound status for PT-141 (Bremelanotide) means the safety profile is characterised by preclinical and limited human data — handle with strict sterile procedure, store at the correct temperatures, and source only from vendors providing complete COA data including endotoxin testing. Sterile reconstitution means: alcohol prep pad on septum, single-use needle, uncontaminated working surface — discard any reconstituted material showing cloudiness or visible particulate. From a handling safety perspective, PT-141 (Bremelanotide) presents typical research compound handling requirements — sterile technique, temperature-appropriate handling throughout, and verified-quality source material are the primary factors.
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
